Close
Top Videos
Top Searches
Moods
Black Lives Matter
Chill
Christmas
Commute
Energy boosters
Feel-Good
Focus
Party
Pride
Romance
Sad
Sleep
Workout
Genres
African
Arabic
Blues
Bollywood & Indian
Christian & Gospel
Classical
Country and Americana
Dance and electronic
Decades
Family
Folk and acoustic
Hip-hop
Indie and alternative
J-Pop
Jazz
K-Pop
Latin
Mandopop & Cantopop
Metal
Pop
R&B and Soul
Reggae and Caribbean
Rock
Soundtracks and musicals
Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics
01:14
|
Download MP3
Related Videos
5:11
iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma
2:01
The evolution of BCL2 inhibition in CLL
1:31
Frontline treatment for CLL: the changing paradigm
4:48
The evolution of alloSCT in Richter's transformation and its combination with biological agents
2:13
Personalizing the timing of SCT in patients with myelofibrosis
2:22
The need for novel agents to treat patients with MCL who have relapsed after targeted therapy
1:36
The use of outpatient cilta-cel in the treatment of multiple myeloma
1:14
Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics
2:19
The addition of venetoclax to hyper-CVAD-nelarabine and pegylated asparagine in T-ALL
1:20
Insights into the diagnosis of smoldering myeloma from a UK perspective & ongoing trials
3:08
Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸
1:53
Challenges in developing immunotherapies for CLL compared to other hematologic malignancies
6:54
Biomarker-guided treatment of CLL in the chemo-free era
5:40
Recommendations for biomarker analysis in CLL: updates from ERIC 2024
2:55
A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib
4:45
Increasing diversity in myeloma clinical trials: addressing disparities & inclusion criteria
2:57
Moving away from chemoimmunotherapy and towards novel targeted agents in CLL
1:45
The role of non-covalent BTKis in the era of covalent BTKis for B-cell malignancies
1:32
Unanswered questions in MCL: when will we achieve cure?
2:17
Key challenges in treating patients with t(11;14) multiple myeloma with BCL2 inhibitors